Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 1.99 | - |
NAV | ₹18.63 | - |
Fund Started | 31 Oct 2022 | - |
Fund Size | ₹1691.09 Cr | - |
Exit Load | Exit load of 1% if redeemed within 180 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 37.75% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
3 Year
5 Year
Equity | 99.08% | - |
Cash | 0.92% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Ipca Laboratories Ltd. | 3.57% |
Max Healthcare Institute Ltd. | 3.12% |
Tata Technologies Ltd | 2.89% |
Glenmark Pharmaceuticals Ltd. | 2.64% |
Amber Enterprises India Ltd. | 2.56% |
Biocon Ltd. | 2.56% |
Fortis Healthcare Ltd. | 2.56% |
Berger Paints India Ltd. | 2.54% |
JSW Infrastructure Ltd. | 2.52% |
The Federal Bank Ltd. | 2.48% |
Name | Satish Ramanathan | - |
Start Date | 01 Oct 2024 | - |
Name
Start Date
Description | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. There is no assurance that the investment objective of the Scheme will be realized. | - |
Launch Date | 31 Oct 2022 | - |
Description
Launch Date